Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure

Bibliography

• MCMAHON EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. (2001) 1(2):190-196.
   PubMedGoogle Scholar
• Simpson SA, Tait JF, Wettstein A, Neher R, von Euw J, Reichstein T: Isolierung eines neuen kristallisierten Hormons aus Nebennieren mit besonders hoher Wirksamkeit auf den Mineralstoffwechsel. Experientia (1953) 9:333-335.
   PubMedGoogle Scholar
• NISHIKAWA T, SUEMATSU S, SAITO J et al.: Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J. Steroid Biochem. Mol. Biol. (2005) 96(3-4):309-316.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, ENEROTH P, KJEKSHUS J, WILHELMSEN L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group. Circulation (1990) 82(5):1730-1736.
   PubMed Web of Science ®Google Scholar
• STAESSEN J, LIJNEN P, FAGARD R, VERSCHUEREN LJ, AMERY A: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. (1981) 91(3):457-465.
   PubMed Web of Science ®Google Scholar
• STRUTHERS AD: Aldosterone blockade in cardiovascular disease. Heart (2004) 90(10):1229-1234.
   PubMed Web of Science ®Google Scholar
• SHARMAN D, MORRIS A, STRUTHERS A: Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. Diabetologia (2007) 50(10):2061-2066.
   PubMed Web of Science ®Google Scholar
• MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation (1999) 100(10):1056-1064.
   PubMed Web of Science ®Google Scholar
• TAKEDA Y, MIYAMORI I, YONEDA T et al.: Production of aldosterone in isolated rat blood vessels. Hypertension (1995) 25(2):170-173.
   PubMed Web of Science ®Google Scholar
• SILVESTRE JS, ROBERT V, HEYMES C et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. (1998) 273(9):4883-4891.
   PubMed Web of Science ®Google Scholar
• CHAI W, DANSER AH: Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch. Pharmacol. (2006) 374(3):153-162.
   PubMed Web of Science ®Google Scholar
• AHOKAS RA, SUN Y, BHATTACHARYA SK, GERLING IC, WEBER KT: Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells. Circulation (2005) 111(1):51-57.
   PubMed Web of Science ®Google Scholar
• ROCHA R, STIER CT Jr, KIFOR I et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 141(10):3871-3878.
   PubMed Web of Science ®Google Scholar
• OBERLEITHNER H, RIETHMULLER C, LUDWIG T, HAUSBERG M, SCHILLERS H: Aldosterone remodels human endothelium. Acta Physiol. (Oxf) (2006) 187(1-2):305-312.
   PubMed Web of Science ®Google Scholar
• HILLEBRAND U, SCHILLERS H, RIETHMULLER C et al.: Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J. Hypertens. (2007) 25(3):639-647.
   PubMed Web of Science ®Google Scholar
• CELIK T, IYISOY A, KURSAKLIOGLU H, ISIK E: Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans? Int. J. Cardiol. (2007) 115(1):97-98.
   PubMed Web of Science ®Google Scholar
• WAKABAYASHI K, SUZUKI H, SATO T et al.: Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int. J. Cardiol. (2006) 107(2):260-266.
   PubMed Web of Science ®Google Scholar
• FARQUHARSON CA, STRUTHERS AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 101(6):594-597.
   PubMed Web of Science ®Google Scholar
• BARR CS, LANG CC, HANSON J et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. (1995) 76(17):1259-1265.
   PubMed Web of Science ®Google Scholar
• MACDONALD JE, KENNEDY N, STRUTHERS AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90(7):765-770.
   PubMed Web of Science ®Google Scholar
• MACFADYEN RJ, BARR CS, STRUTHERS AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. (1997) 35(1):30-34.
   PubMed Web of Science ®Google Scholar
• LOSKUTOFF DJ, QUIGLEY JP: PAI-1, fibrosis, and the elusive provisional fibrin matrix. J. Clin. Invest. (2000) 106(12):1441-1443.
   PubMed Web of Science ®Google Scholar
• MENARD J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol. Cell. Endocrinol. (2004) 217(1-2):45-52.
   PubMed Web of Science ®Google Scholar
• COOK CS, BERRY LM, KIM DH et al.: Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab. Dispos. (2002) 30(12):1344-1351.
   PubMed Web of Science ®Google Scholar
• DELYANI JA: Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. (2000) 57(4):1408-1411.
   PubMed Web of Science ®Google Scholar
• WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41(5):1021-1026.
   PubMed Web of Science ®Google Scholar
• BROWN NJ: Eplerenone: cardiovascular protection. Circulation (2003) 107(19):2512-2518.
   PubMed Web of Science ®Google Scholar
• FDA USFDA: INSPRA™ (eplerenone tablets) – FDA label (2002).
   Google Scholar
• WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15(8):709-716.
   PubMed Web of Science ®Google Scholar
• DELYANI J, MYLES K, FUNDER J: Eplerenone (SC 66110) a highly selective aldosterone antagonist. Am. J. Hypertens. (1998) 11:A94.
   Google Scholar
• FLACK JM, OPARIL S, PRATT JH et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. (2003) 41(7):1148-1155.
   PubMed Web of Science ®Google Scholar
• KRUM H, NOLLY H, WORKMAN D et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 40(2):117-123.
   PubMed Web of Science ®Google Scholar
• BRILLA CG, MATSUBARA LS, WEBER KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell Cardiol. (1993) 25(5):563-575.
   PubMed Web of Science ®Google Scholar
• LACOLLEY P, LABAT C, PUJOL A et al.: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation (2002) 106(22):2848-2853.
   PubMed Web of Science ®Google Scholar
• SCHAFER A, FRACCAROLLO D, HILDEMANN SK et al.: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc. Res. (2003) 58(3):655-662.
   PubMed Web of Science ®Google Scholar
• FRACCAROLLO D, GALUPPO P, HILDEMANN S et al.: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. (2003) 42(9):1666-1673.
   PubMed Web of Science ®Google Scholar
• SUSIC D, VARAGIC J, AHN J, MATAVELLI L, FROHLICH ED: Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am. J. Physiol. Heart Circ. Physiol. (2007) 292(1):H175-H179.
   Google Scholar
• SUZUKI G, MORITA H, MISHIMA T et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 106(23):2967-2972.
   PubMed Web of Science ®Google Scholar
• SHROFF SC, RYU K, MARTOVITZ NL, HOIT BD, STAMBLER BS: Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. (2006) 17(5):534-541.
   PubMed Web of Science ®Google Scholar
• EPSTEIN M AJ, RONIKER B: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension (1999) 33:1075.
   Google Scholar
• CROOM KF, PERRY CM: Eplerenone: a review of its use in essential hypertension. Am. J. Cardiovasc. Drugs (2005) 5(1):51-69.
   PubMedGoogle Scholar
• PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108(15):1831-1838.
   PubMed Web of Science ®Google Scholar
• PRISANT LM, KRUM H, RONIKER B et al.: Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J. Clin. Pharmacol. (2003) 43(11):1203-1210.
   PubMed Web of Science ®Google Scholar
• NISHIZAKA MK, ZAMAN MA, CALHOUN DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. (2003) 16(11):925-930.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348(14):1309-1321.
   PubMed Web of Science ®Google Scholar
• PITT B, GHEORGHIADE M, ZANNAD F et al.: Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur. J. Heart Fail. (2006) 8(3):295-301.
   PubMed Web of Science ®Google Scholar
• Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am. J. Cardiol. (1996) 78(8):902-907.
   PubMed Web of Science ®Google Scholar
• JUURLINK DN, MAMDANI MM, LEE DS et al.: Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. (2004) 351(6):543-551.
   PubMed Web of Science ®Google Scholar
• PITT B, FERRARI R, GHEORGHIADE M et al.: Aldosterone blockade in post-acute myocardial infarction heart failure. Clin. Cardiol. (2006) 29(10):434-438.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, O'MEARA E: Treatment of heart failure with spironolactone–trial and tribulations. N. Engl. J. Med. (2004) 351(6):526-528.
   PubMed Web of Science ®Google Scholar
• EPSTEIN M, WILLIAMS GH, WEINBERGER M et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. In: (2006):940-951.
   Google Scholar
• GOSSE P, MACFADYEN RJ: Does eplerenone have a future in the management of hypertension in Europe? J. Hum. Hypertens. (2006) 20(11):829-832.
   PubMed Web of Science ®Google Scholar